In the past week, SRPT stock has gone up by 0.76%, with a monthly decline of -5.39% and a quarterly plunge of -19.25%. The volatility ratio for the week is 5.85%, and the volatility levels for the last 30 days are 3.87% for Sarepta Therapeutics Inc The simple moving average for the past 20 days is -0.34% for SRPT’s stock, with a -15.18% simple moving average for the past 200 days.
Is It Worth Investing in Sarepta Therapeutics Inc (NASDAQ: SRPT) Right Now?
Sarepta Therapeutics Inc (NASDAQ: SRPT) has a price-to-earnings ratio that is above its average at 45.17x. The stock has a 36-month beta value of 0.74. Opinions on the stock are mixed, with 12 analysts rating it as a “buy,” 9 as “overweight,” 1 as “hold,” and 1 as “sell.”
The public float for SRPT is 91.25M, and at present, short sellers hold a 5.39% of that float. On March 06, 2025, the average trading volume of SRPT was 811.35K shares.
SRPT) stock’s latest price update
The stock price of Sarepta Therapeutics Inc (NASDAQ: SRPT) has jumped by 4.68 compared to previous close of 102.86. Despite this, the company has seen a gain of 0.76% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-04 that Sarepta Therapeutics’ stock is at 52-week lows despite strong Q4 earnings and promising clinical updates, reflecting broader biotech sector challenges and investor sentiment. Q4 2024 earnings showed 75% Y/Y revenue growth, driven by Elevidys, with net income tripling to $159.049 million and EPS of $1.50. Sarepta’s pipeline includes gene therapies for LGMD, FSHD, and DM1, with significant market potential, though not as large as DMD.
Analysts’ Opinion of SRPT
Many brokerage firms have already submitted their reports for SRPT stocks, with Deutsche Bank repeating the rating for SRPT by listing it as a “Hold.” The predicted price for SRPT in the upcoming period, according to Deutsche Bank is $136 based on the research report published on February 11, 2025 of the current year 2025.
Needham, on the other hand, stated in their research note that they expect to see SRPT reach a price target of $202, previously predicting the price at $205. The rating they have provided for SRPT stocks is “Buy” according to the report published on November 27th, 2024.
H.C. Wainwright gave a rating of “Sell” to SRPT, setting the target price at $80 in the report published on November 25th of the previous year.
SRPT Trading at -6.36% from the 50-Day Moving Average
After a stumble in the market that brought SRPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -37.85% of loss for the given period.
Volatility was left at 3.87%, however, over the last 30 days, the volatility rate increased by 5.85%, as shares sank -5.62% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.46% lower at present.
During the last 5 trading sessions, SRPT rose by +0.76%, which changed the moving average for the period of 200-days by -18.74% in comparison to the 20-day moving average, which settled at $108.03. In addition, Sarepta Therapeutics Inc saw -11.45% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SRPT starting from Wigzell Hans Lennart Rudolf, who sale 10,500 shares at the price of $124.84 back on Dec 12 ’24. After this action, Wigzell Hans Lennart Rudolf now owns 22,840 shares of Sarepta Therapeutics Inc, valued at $1,310,820 using the latest closing price.
Wigzell Hans Lennart Rudolf, the Director of Sarepta Therapeutics Inc, proposed sale 10,500 shares at $124.80 during a trade that took place back on Dec 12 ’24, which means that Wigzell Hans Lennart Rudolf is holding shares at $1,310,400 based on the most recent closing price.
Stock Fundamentals for SRPT
Current profitability levels for the company are sitting at:
- 0.11 for the present operating margin
- 0.83 for the gross margin
The net margin for Sarepta Therapeutics Inc stands at 0.12. The total capital return value is set at 0.07. Equity return is now at value 19.71, with 6.51 for asset returns.
Based on Sarepta Therapeutics Inc (SRPT), the company’s capital structure generated 0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.15. The debt to equity ratio resting at 0.87. The interest coverage ratio of the stock is 11.86.
Currently, EBITDA for the company is 316.89 million with net debt to EBITDA at 0.74. When we switch over and look at the enterprise to sales, we see a ratio of 5.61. The receivables turnover for the company is 2.93for trailing twelve months and the total asset turnover is 0.48. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.20.
Conclusion
To sum up, Sarepta Therapeutics Inc (SRPT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
